NCT02527200 - Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2015

Primary Completion Date

November 4, 2020

Study Completion Date

November 19, 2020

Conditions

Metabolism and Nutrition DisorderObesity

Interventions

DRUG

liraglutide

Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

DRUG

placebo

Trial Locations (32)

1023

Novo Nordisk Investigational Site, Grafton

2050

Novo Nordisk Investigational Site, Camperdown

3052

Novo Nordisk Investigational Site, Parkville

11501

Novo Nordisk Investigational Site, Mineola

13385

Novo Nordisk Investigational Site, Marseille Cédex 05

14203

Novo Nordisk Investigational Site, Buffalo

20132

Novo Nordisk Investigational Site, Milan

21229

Novo Nordisk Investigational Site, Baltimore

29609

Novo Nordisk Investigational Site, Brest

31059

Novo Nordisk Investigational Site, Toulouse

33076

Novo Nordisk Investigational Site, Bordeaux

34093

Novo Nordisk Investigational Site, Istanbul

34295

Novo Nordisk Investigational Site, Montpellier

34890

Novo Nordisk Investigational Site, Istanbul

35128

Novo Nordisk Investigational Site, Padua

43235

Novo Nordisk Investigational Site, Columbus

49033

Novo Nordisk Investigational Site, Angers

55139

Novo Nordisk Investigational Site, Samsun

59037

Novo Nordisk Investigational Site, Lille

61080

Novo Nordisk Investigational Site, Trabzon

67504

Novo Nordisk Investigational Site, Haguenau

69677

Novo Nordisk Investigational Site, Bron

75012

Novo Nordisk Investigational Site, Paris

75015

Novo Nordisk Investigational Site, Paris

76031

Novo Nordisk Investigational Site, Rouen

90404

Novo Nordisk Investigational Site, Santa Monica

T3B 6A8

Novo Nordisk Investigational Site, Calgary

H4A 3J1

Novo Nordisk Investigational Site, Montreal

06200

Novo Nordisk Investigational Site, Nice

00050

Novo Nordisk Investigational Site, Fiumicino

3015 CN

Novo Nordisk Investigational Site, Rotterdam

06010

Novo Nordisk Investigational Site, Ankara